Anticonvulsant activity of newer substituted 5-aryl/diphenylmethyl-3-alkyl-2-oxazolidones.
D000328:Adult; D000818:Animals; D000927:Anticonvulsants; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D004357:Drug Synergism; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007928:Lethal Dose 50; D008297:Male; D008996:Monoamine Oxidase Inhibitors; D010080:Oxazoles / Q000494:pharmacology* / Q000633:toxicity; D010424:Pentobarbital / Q000494:pharmacology; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D051381:Rats; D012890:Sleep / Q000187:drug effects; D013329:Structure-Activity Relationship; D013997:Time Factors
D000927:Anticonvulsants; D008996:Monoamine Oxidase Inhibitors; D010080:Oxazoles; D010424:Pentobarbital; D010433:Pentylenetetrazole